Neurodegenerative Diseases

Featured Article

Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are

Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are

Because of dementia's prolonged disease course, advance care decisions and planning are often overlooked until it is too late.

Latest

Monoclonal Antibody Granted Orphan Drug Status for Frontotemporal Dementia

Monoclonal Antibody Granted Orphan Drug Status for Frontotemporal Dementia

There are currently no treatments available for frontotemporal dementia.

PET Imaging Can Measure Synaptic Loss From Alzheimer's

PET Imaging Can Measure Synaptic Loss From Alzheimer's

Positron emission tomographic imaging can directly measure synaptic loss with Alzheimer disease.

Confabulations Linked to Impaired Mental Time Travel in Alzheimer Disease

Confabulations Linked to Impaired Mental Time Travel in Alzheimer Disease

The findings suggest that confabulations by patients with AD are related to an impaired ability to mentally go back in time to retrieve the context in which the confabulated memories were encoded.

Link Between Lower Cognitive Ability in Young Adults and Risk for Dementia

Link Between Lower Cognitive Ability in Young Adults and Risk for Dementia

Lower cognitive ability total and verbal ability scores were predictive of greater risk for early-onset dementia.

Treatment for Alzheimer-Related Agitation Gets Fast Track Status

Treatment for Alzheimer-Related Agitation Gets Fast Track Status

Currently, there are no approved treatments for behavioral symptoms in Alzheimer disease.

Midlife Cognition, Vascular Health Predict Dementia and Cognitive Impairment Later in Life

Midlife Cognition, Vascular Health Predict Dementia and Cognitive Impairment Later in Life

Investigators reviewed data from patients aged 45 to 64 years who were enrolled in the Atherosclerosis Risk in Communities Study and who attended additional visits for cognitive function evaluation and repeat cardiovascular risk factor assessment.

Positive PET Results and Hippocampal Volume Predict Progression From MCI to Dementia

Positive PET Results and Hippocampal Volume Predict Progression From MCI to Dementia

An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.

HTT CAG Repeat Size, Age at Onset Associated With Huntington Disease Progression

HTT CAG Repeat Size, Age at Onset Associated With Huntington Disease Progression

Investigators sought to assess factors contributing to progression of functional, cognitive, and motor impairment in Huntington disease.

Diagnosis, Treatments Affected by Amyloid Results in Dementia, Nondementia Patients

Diagnosis, Treatments Affected by Amyloid Results in Dementia, Nondementia Patients

In patients with and without dementia, amyloid-positive and negative results were significantly linked to diagnoses and treatment changes.

Amyloid PET Tied to Diagnostic Changes in Memory Clinic Cohort

Amyloid PET Tied to Diagnostic Changes in Memory Clinic Cohort

For an unselected memory clinic cohort, amyloid PET results are associated with changes in etiology, diagnostic confidence, and patient treatment.

Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds

Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds

While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.

Lifestyle, Behavioral Factors Contribute to Dementia Risk Assessment

Lifestyle, Behavioral Factors Contribute to Dementia Risk Assessment

Decision tree and random forest classification models were used to find associations between patient demographic and lifestyle risk factors with dementia status during more than 30 years of follow-up.

Salivary Levels of Total Huntington Protein Promising as Biomarker for Huntington Disease

Salivary Levels of Total Huntington Protein Promising as Biomarker for Huntington Disease

Measurement of the disease protein huntingtin in saliva may be promising as an accessible, noninvasive biomarker to predict symptom severity and disease course in individuals with Huntington disease.

Trials for Investigational Alzheimer's Tx Lanabecestat Discontinued

Trials for Investigational Alzheimer's Tx Lanabecestat Discontinued

Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.

Higher Blood Pressure at Mid-Life Increases Dementia Risk

Higher Blood Pressure at Mid-Life Increases Dementia Risk

The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.

Intellectual Activities in Later Life May Cut Dementia Risk

Intellectual Activities in Later Life May Cut Dementia Risk

Active participation in intellectual activities among adults aged 65 years or older is associated with reduced risk of dementia.

Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults

Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults

Using the Visual Association Test along with the Mini Mental State Examination may improve predictive value to screen for cognitive deficits.

Lifetime Risks Temper Biomarker Tests for Alzheimer Disease Dementia

Lifetime Risks Temper Biomarker Tests for Alzheimer Disease Dementia

The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.

GRN Mutations May Modify Risk for Frontotemporal Lobar Degeneration

GRN Mutations May Modify Risk for Frontotemporal Lobar Degeneration

In the discovery stage, genome-wide and logistic and linear regression analyses were performed to examine the association of genetic variants with risk for disease and age at onset in those with a GRN mutation and controls who were free of neurodegenerative disorders.

APOE Status May Modulate Neurodegeneration Risk Based on Sex

APOE Status May Modulate Neurodegeneration Risk Based on Sex

The investigators analyzed specific AD biomarkers, including β-amyloid 42, total tau, and phosphorylated tau measured in CSF.

Sign Up for Free e-newsletters



CME Focus